MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Capricor Therapeutics Inc

Ouvert

12.76 -6.25

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.67

Max

13.47

Chiffres clés

By Trading Economics

Revenu

5.4M

-7.1M

Ventes

8.9M

11M

BPA

-0.16

Marge bénéficiaire

-63.938

Employés

160

EBITDA

5.3M

-7.3M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+228.31% upside

Dividendes

By Dow Jones

Prochains Résultats

12 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-41M

544M

Ouverture précédente

19.01

Clôture précédente

12.76

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Capricor Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mars 2025, 15:41 UTC

Principaux Mouvements du Marché

Capricor Therapeutics Shares Rise on FDA Priority Review

Comparaison

Variation de prix

Capricor Therapeutics Inc prévision

Objectif de Prix

By TipRanks

228.31% hausse

Prévisions sur 12 Mois

Moyen 43.6 USD  228.31%

Haut 77 USD

Bas 25 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

5

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

9.45 / 14.45Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.